Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

256
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
256
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Dosage Regimen: Multiple Oral Dosage01:25

Dosage Regimen: Multiple Oral Dosage

232
Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
232
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

2.3K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.3K
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

166
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
166
Dosage Interval and Administration Route: Determination Methods01:19

Dosage Interval and Administration Route: Determination Methods

226
A medication’s effectiveness largely depends on its appropriate dosage and the route of administration. Dosage ensures that a sufficient drug concentration is maintained in the bloodstream to elicit the desired therapeutic effect without causing toxicity. The route of administration affects the drug's bioavailability, rate of absorption, and onset of action, which are crucial for achieving optimal therapeutic outcomes. Drug dosage calculations are critical to tailoring therapy to...
226

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Flucloxacillin plasma and urinary concentrations with and without probenecid and urinary biomarker profiles in healthy volunteers.

British journal of clinical pharmacology·2026
Same author

Mind the Gap: Unraveling the Pharmacokinetic Variability of Δ9-Tetrahydrocannabinol (THC).

Journal of clinical pharmacology·2026
Same author

The Evolving Epidemiology of Invasive Pneumococcal Disease in Australian Children: A Multicentre Retrospective Observational Study.

Open forum infectious diseases·2026
Same author

<i>Streptococcus Pyogenes</i> and Acute Rheumatic Fever: How Strong are the Links in the Chain?

Global heart·2026
Same author

Cefazolin for Methicillin-Susceptible <i>Staphylococcus aureus</i> Bacteremia.

The New England journal of medicine·2026
Same author

Tobramycin pharmacokinetic and pharmacodynamic targets in people with cystic fibrosis.

British journal of clinical pharmacology·2026

Related Experiment Video

Updated: Jan 17, 2026

Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals
04:28

Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals

Published on: March 23, 2016

13.2K

Ivermectin dosing for children under 2 years.

Wenyu Yang1, Andrew Steer2,3, Ben Coghlan4

  • 1School of Pharmacy, Fudan University, No. 826, Zhangheng Road, Pudong New Area, Shanghai, China.

The Journal of Antimicrobial Chemotherapy
|September 23, 2025
PubMed
Summary
This summary is machine-generated.

A new ivermectin dosing strategy for children under two years old was developed. This aims to provide safe and effective scabies treatment for young children, pending clinical trial evaluation.

More Related Videos

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

12.0K
Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections
06:19

Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections

Published on: October 11, 2024

3.4K

Related Experiment Videos

Last Updated: Jan 17, 2026

Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals
04:28

Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals

Published on: March 23, 2016

13.2K
Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

12.0K
Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections
06:19

Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections

Published on: October 11, 2024

3.4K

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Pediatric Pharmacology
  • Dermatology

Background:

  • Ivermectin is an effective scabies treatment but lacks a licensed dosage for children under 15 kg.
  • There is a need for a safe and effective ivermectin dosing strategy in young children.

Purpose of the Study:

  • To identify an ivermectin dosing strategy for children aged under 2 years.
  • To achieve therapeutic drug exposure levels comparable to older children.

Main Methods:

  • A population pharmacokinetic (PopPK) model incorporating CYP3A4 enzyme maturation was utilized.
  • Simulations were performed for three age subgroups under 2 years.
  • Doses were adjusted to achieve a target plasma area under the concentration-time curve (AUC0-∞) and rounded to feasible tablet fractions.

Main Results:

  • For infants aged 3-7 months, 0.75 mg (1/4 tablet) yielded a median AUC0-∞ of 835 μg/L h.
  • For infants aged 8-12 months, 1.5 mg (1/2 tablet) yielded a median AUC0-∞ of 848 μg/L h.
  • For children aged 13-24 months, 3 mg (1 tablet) yielded a median AUC0-∞ of 1033 μg/L h. All doses achieved target exposures.

Conclusions:

  • A pediatric ivermectin dosing strategy for children aged 3 months to 2 years was successfully developed.
  • The proposed regimen is based on a CYP3A4 maturation-based PopPK model.
  • This strategy requires evaluation in a clinical trial for safe and effective scabies treatment in young children.